Lei Liu

Lei Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Cancer
Verified
Journal Article
Open access
JZJiarong Zhang
Jiarong Zhang
JZJinli Zhang
Jinli Zhang
CZChunbo Zhao
Chunbo Zhao
HSHong Sui
Hong Sui
CLChun Feng Li
Chun Feng Li
LLLei Liu
Lei Liu
Background: In the past few decades, natural products have become an increasingly important source of potential anti-cancer agents. The green walnut husk(GWH) extracts have been reported to inhibit multiple tumor cells and might be a promising chemopreventive agent in human neoplasia. However, it is not clear whether GWH extracts inhibit gastric cancer.

4 May 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
JZJinli Zhang
Jinli Zhang
LYLu Yang
Lu Yang
FKFanwei Kong
Fanwei Kong
DWDi Wu
Di Wu
BHBaoru Hu
Baoru Hu
LLLei Liu
Lei Liu
Approximately 5% of advanced colorectal carcinomas (CRCs) and 12–15% of early CRCs are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Nowadays, PD-L1 inhibitors or combined CTLA4 inhibitors are the major strategies for advanced or metastatic MSI-H colorectal cancer, but some people still show drug resistance or progression. Combined immunotherapy has been shown to expand the benefit population in non-small-cell lung carcinoma (NSCLC), hepatocellular carcinoma (HCC), and other tumors while reducing the incidence of hyper-progression disease (HPD). Nevertheless, advanced CRC with MSI-H remains rare. In this article, we describe a case of an elder patient with MSI-H advanced CRC carrying MDM4 amplification and DNMT3A co-mutation who responded to sintilimab plus bevacizumab and chemotherapy as the first-line treatment without obvious immune-related toxicity. Our case provides a new treatment option for MSI-H CRC with multiple risk factors of HPD and highlights the importance of predictive biomarkers in personalized immunotherapy.